Pre-treatment calprotectin (MRP8/14) provides no added value to testing CRP alone in terms of predicting response to TNF inhibitors in rheumatoid arthritis in a post hoc analysis.
Samantha Louise SmithSheree AlexanderNisha NairSebastien ViatteStephen EyreKimmie L HyrichAnn W MorganAnthony G WilsonJohn Dudley IsaacsDarren PlantRichard B WarrenPublished in: Annals of the rheumatic diseases (2023)
Beyond correlation with CRP, we found no evidence to suggest that MRP8/14 explains additional variability in response to TNFi in patients with RA over and above CRP alone.